Sequential Therapy versus Standard Triple Therapy for Helicobacter Pylori Eradication in Iran: a double-blind, randomized, placebo-controlled trial

Abstract

Background and aim: Currently, different regimens are used for Helicobacter pylori eradication. The aim of this study is to compare the efficacy and safety of sequential and standard triple therapy for Helicobacter pylori eradication in Bandar Abbas in 2018. Methods: This randomized controlled trial was done on 150 patients in Bandar Abbas in 2018. Patients were randomly assigned into two groups either to receive standard triple therapy or sequential therapy for Helicobacter pylori eradication. Patients were followed for helicobacter eradication, minor and major side effects and drug intolerance. Data were analyzed using SPSS 23.0 software. Results: Two groups were similar in baseline characteristics. Helicobacter pylori eradication was reported in 70 (90.9 %) in the sequential and 54 (74 %) in the standard triple therapy group (p=0.006). Minor side effects were reported in 20 (26 %) in the sequential and 36 (49.3 %) in the standard triple therapy (p=0.003). Major side effects (p=0.142) and drug intolerance (p=0.480) were similar in both groups. Conclusion: Sequential therapy is more effective and has lower rate of minor complications in eradication of Helicobacter pylori. Trial registration: The protocol of study was registered at the Iranian Registry of Clinical Trials (IRCT) with ID number of IRCT20180131038581N2. Funding: Hormozgan University of Medical Sciences, thesis number: 93-95/231